{"disease":{"id":"nmibc","name":"nmibc"},"drugs":{"marketed":[{"drug_id":"inbakicept","indication_name":"BCG-unresponsive NMIBC with CIS","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Anktiva","generic_name":"INBAKICEPT","company_name":"Altor Bioscience, Llc, An Indirect Wholly-Owned Su","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":40,"revenue":null,"mechanism":"Anktiva works by targeting a specific target to treat BCG-unresponsive nonmuscle invasive bladder cancer."},{"drug_id":"inbakicept","indication_name":"BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Anktiva","generic_name":"INBAKICEPT","company_name":"Altor Bioscience, Llc, An Indirect Wholly-Owned Su","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":40,"revenue":null,"mechanism":"Anktiva works by targeting a specific target to treat BCG-unresponsive nonmuscle invasive bladder cancer."},{"drug_id":"bcg","indication_name":"Treatment of non-muscle invasive bladder cancer (NMIBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of high-grade non-muscle invasive bladder cancer (NMIBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of high-risk non-muscle invasive bladder cancer (NMIBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of non-muscle invasive bladder cancer (NMIBC) with high-grade tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of non-muscle invasive bladder cancer (NMIBC) with high-risk tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC))","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":21,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05176145","title":"Demonstration of the Medical Interest of the VisioCyt® Artificial Intelligence Test","phase":"NA","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Vitadx","has_results":false},{"nct_id":"NCT06982690","title":"Anesthesia Modality and Oncologic Outcomes in High-Risk NMIBC: A Randomized Trial","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":370,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT06991868","title":"A Multicenter Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Microscopic Residual Disease (MRD)","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT03148158","title":"Assessment Of Bladder Tumors Stage And Grade By Outpatient Flexible Cystoscopy Performed By Urology Resident","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Mansoura University","has_results":false},{"nct_id":"NCT07207824","title":"DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":182,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06696794","title":"Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Shaogang Wang","has_results":false},{"nct_id":"NCT07322263","title":"Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":174,"lead_sponsor_name":"Michael A. O'Donnell","has_results":false},{"nct_id":"NCT07445308","title":"The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Shenyang Sunshine Pharmaceutical Co., LTD.","has_results":false},{"nct_id":"NCT05943379","title":"RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":85,"lead_sponsor_name":"RemeGen Co., Ltd.","has_results":false},{"nct_id":"NCT07122414","title":"A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Suzhou Forlong Biotechnology Co., Ltd","has_results":false},{"nct_id":"NCT06889623","title":"Immediate Chemotherapy Following Resection for High-Risk Non-Muscle-Invasive Bladder Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":72,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT06351904","title":"A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":72,"lead_sponsor_name":"Ractigen Therapeutics.","has_results":false},{"nct_id":"NCT06735287","title":"A Bladder-Sparing Treatment Strategies of Large-Volume Non-Muscle-Invasive Bladder Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT06588179","title":"SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":58,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT07187063","title":"Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"Lahey Clinic","has_results":false},{"nct_id":"NCT06069453","title":"Hyaluronic Acid Sodium Salt and Hydeal-D in the Management of LUTS After TURBT for NMIBC.","phase":"NA","overall_status":"TERMINATED","enrollment_count":54,"lead_sponsor_name":"Fidia Farmaceutici s.p.a.","has_results":false},{"nct_id":"NCT05375903","title":"A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"UroGen Pharma Ltd.","has_results":false},{"nct_id":"NCT05014139","title":"A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":37,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT03719300","title":"Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":32,"lead_sponsor_name":"Anchiano Therapeutics Israel Ltd.","has_results":true},{"nct_id":"NCT07064863","title":"A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":31,"lead_sponsor_name":"Queen's University","has_results":false},{"nct_id":"NCT07100184","title":"RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT07053748","title":"Observational Clinical Study on High - Risk NMIBC Patients Choosing Trimodality Bladder - Sparing Therapy","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT07339761","title":"Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT03914794","title":"A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","has_results":false},{"nct_id":"NCT06181266","title":"A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":22,"lead_sponsor_name":"Prokarium Ltd","has_results":false},{"nct_id":"NCT02009332","title":"Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Aadi Bioscience, Inc.","has_results":true},{"nct_id":"NCT07505615","title":"A Phase I-II Study of Novel Oncolytic Virus VG161 Via Intravesical Instillation for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Ding-Wei Ye","has_results":false},{"nct_id":"NCT03053635","title":"Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Theralase® Technologies Inc.","has_results":false},{"nct_id":"NCT03167151","title":"Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"University of Oxford","has_results":true},{"nct_id":"NCT03672240","title":"Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Asieris Pharmaceutical Technologies Co., Ltd.","has_results":false},{"nct_id":"NCT06810141","title":"ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"ImmunityBio, Inc.","has_results":false}],"total":31},"guidelines":[],"source":"Drug Landscape verified database"}